TY  - GEN
TY  - GEN
T1  - Handbook of HER2-targeted agents in breast cancer
A1  - Alvarez, Ricardo H.
A2  - Cortés, Javier.
A2  - Mattos-Arruda, Leticia.
A2  - Falzon, Mary.
A2  - Fasolo, Angelica.
A2  - Gandy, Michael.
A2  - Gianni, Luca.
A2  - Harbeck, Nadia.
A2  - Piccart, Martine.
A2  - Zambelli, Stefania.
A2  - Zardavas, Dimitrios.
LA  - English
PP  - Tarporley
PB  - Springer Healthcare Ltd. : Imprint: Springer Healthcare
YR  - 2013
ED  - 1st ed. 2013.
UL  - http://discoverylib.upm.edu.my/discovery/Record/978-1-907673-94-8
AB  - Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year.  Of these cases, approximately  15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes.  However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer  provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.
OP  - 96
CN  - RC254-282
SN  - 9781907673948
KW  - Oncology  .
KW  - Primary care (Medicine).
KW  - General practice (Medicine).
KW  - Internal medicine.
KW  - Pharmacotherapy.
KW  - Oncology.
KW  - Primary Care Medicine.
KW  - General Practice / Family Medicine.
KW  - Internal Medicine.
ER  -